🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great summary of the results of our study on #immunosupressives discontinuation in #lupus nephritis.

Kidney whole-transcriptome profiling in primary #antiphospholipid syndrome reveals #complement, #interferons and #NETs-related gene expression academic.oup.com/rheumatology/a…

🔍 Real-world data on #LupusNephritis: achieving EULAR/ERA-EDTA therapy targets👥 140 LN Patients. Treatments: 51.4% CYC, 32.1% MMF ✅ 69.2% achieved renal response at 12 months -Response Rates: - 3 months: 72.6% - 6 months: 78.5% - 12 months: 69.2% 🔽 Increased

#Frailty assessed by the Systemic Lupus International Collaborating Clinics-Frailty Index (#SLICC-FI) is independently associated with #atherosclerotic plaques in patients with systemic #lupus erythematosus. rmdopen.bmj.com/content/10/3/e…

High prevalence of poorly managed cardiovascular risk factors found among patients with #SystemicLupusErythematosus, particularly among individuals from middle-income countries and those with #AntiphospholipidSyndrome: cutt.ly/6eUINmqm

Check out our open access article: Atherosclerotic plaque progression and incident #CVD events in a 10-year prospective study of patients with #SLE: the impact of persistent CVD risk factor target attainment and sustained DORIS remission ACR_Journals acrjournals.onlinelibrary.wiley.com/doi/abs/10.100…

#CVD events in #SLE 🗒️✏️ ☑️CV risk factors (BP, lipids, smoking, BMI, physical activity) well controlled?? ☑️DORIS remission achieved?? ☑️Persistant triple #aPL ?? 🆕📖👇 ACR_Journals

Great study by Maria Tektonidou in @ACR_journals. Meeting targets of traditional risk factors (e.g. #cholesterol, BP) and remission of #SLE disease activity significantly attenutate the increased #CVD risk in #Lupus during 10 year followup! #cardiorheum acrjournals.onlinelibrary.wiley.com/doi/10.1002/ar…

Over 10-year follow-up, patients with SLE had a 2.3-fold higher risk of new carotid atherosclerotic plaques. CV risk factor control and prolonged clinical remission reduced risk. Persistent triple aPL+ was assoc with increased incidence of CVD events A&R doi.org/10.1002/art.43…

A Modifiable Vascular Risk in SLE Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece. buff.ly/4fJkXcl

Data from our study are published by Medscape and MedPage buff.ly/4fJkXcl medscape.com/viewarticle/lu…

Looking forward to Lupus 2025!

With great pleasure, we organize, for one more year, the 2nd Greek Congress for SpA, with distinguished national and international speakers! spondyloarthritis.gr Stefan Siebert Armen Yuri Gasparyan Olena Zimba Maria Tektonidou rheum_appk Christos Koutsianas ImmunRheumGr Konstantinos Thomas

Subclinical #Atherosclerosis Risk Can Be Predicted in Female Patients With #SLE Using #Metabolomic Signatures pubmed.ncbi.nlm.nih.gov/40194967/

Warm congratulations to Zahi Touma, MD, PhD and all Lupus 2025 organisers for such a successful #LUPUS2025 congress! We learned a lot, had the opportunity to share our work, meet legends from the Toronto Clinic and had the honour to co-moderate sessions with them. Thank you!

Very happy to share our review article ‘Towards precision medicine in #Antiphospholipid syndrome’ published in the #Lancet Rheumatology The Lancet Rheumatology (free access) sciencedirect.com/science/articl…

Review outlines how precision medicine could transform the management of #AntiphospholipidSyndrome by using genetic, molecular, & clinical data to tailor treatment. Advances in omics & AI may lead to more effective, individualised care: cutt.ly/DrnrUeKP Maria Tektonidou

Our presentation at Lupus 2025 on ‘10-year atherosclerotic plaque progression and incident #CVD in #SLE’ (Arthritis Rheumatology, doi: 10.1002/art.43097) gained attention by #Medscape ‘’Remission, Attaining CV Risk Targets Drops CVD Risk in Lupus” medscape.com/viewarticle/re…

Thank you The Lancet Rheumatology for the opportunity to discuss the current evidence towards #Precision medicine in #Antiphospholipid syndrome, a rare disorder with therapeutic unmet needs.

❤️ ERN ReCONNET joins #WorldAPSday! 🩸 💪The ERN ReCONNET APS Disease Group is proudly chaired by 🔹Maria Tektonidou 🔹Savino Sciascia 🔹Silvia Aguilera 🌐For resources and more information, visit: reconnet.ern-net.eu/disease-aps/ 📍Come and visit booth #O7 at EULAR 2025